Deal Library / Pharma BD Deal Intelligence

Merck & Co. Inc. — Pharma Deals

The Pharma Closeout tracks 48 deals, $219.1B in disclosed deal value, 35 with a post-close Outcome Score for Merck & Co. Inc..

Median Critic Score: 80  ·  Median Outcome Score: 58

Best outcome: Merck & Co. Inc. / Acceleron Pharma Inc. (90)  ·  Weakest outcome: Merck & Co. Inc. / Sirna Therapeutics Inc. (8)

All 48 deals

• Merck & Co. Inc. / Acceleron Pharma Inc. — 2021 · $11.5B · Worked — the deal delivered on its rationale.
• Merck & Co. Inc. / Peloton Therapeutics Inc. — 2019 · $2.2B · Worked — the deal delivered on its rationale.
• Merck & Co. Inc. / AstraZeneca PLC — 2017 · $8.5B · Worked — the deal delivered on its rationale.
• Merck & Co. Inc. / Moderna, Inc. — 2022 · $250M · Worked — the deal delivered on its rationale.
• Merck & Co. Inc. / Moderna, Inc. — 2016 · $250M · Worked — the deal delivered on its rationale.
• Merck & Co. Inc. / Eisai Co., Ltd. — 2018 · $5.8B · Worked — the deal delivered on its rationale.
• Merck & Co. Inc. / Prometheus Biosciences Inc. — 2023 · $10.8B · Worked — the deal delivered on its rationale.
• Merck & Co. Inc. / Bristol-Myers Squibb Company — 2017 · $625M · Largely worked — most objectives met.
• Merck & Co. Inc. / Schering-Plough Corp. — 2009 · $41.1B · Largely worked — most objectives met.
• Merck & Co. Inc. / Daiichi Sankyo Company, Limited — 2023 · $22.0B · Largely worked — most objectives met.
• Merck & Co. Inc. / Harpoon Therapeutics — 2024 · $680M · Largely worked — most objectives met.
• Merck & Co. Inc. / Banyu Pharmaceutical Co. Ltd. — 2003 · $1.5B · Largely worked — most objectives met.
• Merck & Co. Inc. / Proxygen GmbH — 2023 · $2.5B · Largely worked — most objectives met.
• Merck & Co. Inc. / VelosBio Inc. — 2020 · $2.8B · Largely worked — most objectives met.
• Merck & Co. Inc. / EyeBio Ltd. — 2024 · $3.0B · Largely worked — most objectives met.
• Merck & Co. Inc. / Imago BioSciences Inc. — 2022 · $1.4B · Largely worked — most objectives met.
• Merck & Co. Inc. / Kelun-Biotech Biopharmaceuticals Co. Ltd. — 2022 · $936M · Largely worked — most objectives met.
• Merck & Co. Inc. / ArQule Inc. — 2019 · $2.7B · Mixed — partial payoff, real shortfalls.
• Merck & Co. Inc. / Eisai Co., Ltd. — 2017 · $5.8B · Mixed — partial payoff, real shortfalls.
• Merck & Co. Inc. / Schering-Plough Corporation (joint venture, ezetimibe) — 2000 · Mixed — partial payoff, real shortfalls.
• Merck & Co. Inc. / Pandion Therapeutics — 2021 · $1.9B · Mixed — partial payoff, real shortfalls.
• Merck & Co. Inc. / Modifi Biosciences — 2024 · $1.3B · Mixed — partial payoff, real shortfalls.
• Merck & Co. Inc. / Protillion Biosciences, Inc. — 2026 · $510M · Mixed — partial payoff, real shortfalls.
• Merck & Co. Inc. / Seagen Inc. — 2019 · $4.2B · Mixed — partial payoff, real shortfalls.
• Merck & Co. Inc. / Organon & Co. — 2007 · $14.4B · Mixed — partial payoff, real shortfalls.
• Merck & Co. Inc. / Cubist Pharmaceuticals — 2014 · $9.5B · Underwhelmed — fell short of the thesis.
• Merck & Co. Inc. / Aton Pharma Inc. — 2004 · Underwhelmed — fell short of the thesis.
• Merck & Co. Inc. / Seagen Inc. — 2020 · $4.2B · Did not work — the deal failed to deliver.
• Merck & Co. Inc. / Rosetta Inpharmatics Inc. — 2001 · $540M · Did not work — the deal failed to deliver.
• Merck & Co. Inc. / Inspire Pharmaceuticals, Inc. — 2011 · $430M · Did not work — the deal failed to deliver.
• Merck & Co. Inc. / SmartCells, Inc. — 2010 · $500M · Did not work — the deal failed to deliver.
• Merck & Co. Inc. / Insmed Inc. (Follow-on Biologics platform) — 2009 · $130M · Did not work — the deal failed to deliver.
• Merck & Co. Inc. / Idenix Pharmaceuticals — 2014 · $3.9B · Did not work — the deal failed to deliver.
• Merck & Co. Inc. / NovaCardia Inc. — 2007 · $366M · Did not work — the deal failed to deliver.
• Merck & Co. Inc. / Sirna Therapeutics Inc. — 2006 · $1.1B · Did not work — the deal failed to deliver.
• Merck & Co. Inc. / Terns Pharmaceuticals, Inc. — 2026 · $6.7B
• Merck & Co. Inc. / Verona Pharma plc — 2025 · $10.0B
• Merck & Co. Inc. / Cidara Therapeutics, Inc. — 2025 · $9.2B
• Merck & Co. Inc. / Jiangsu Hengrui Pharmaceuticals Co. Ltd. — 2025 · $2.0B
• Merck & Co. Inc. / LaNova Medicines Ltd. — 2024 · $3.3B
• Merck & Co. Inc. / Curon Biopharmaceutical (Shanghai) Co. Ltd. — 2024 · $1.3B
• Merck & Co. Inc. / Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. — 2023 · $9.5B
• Merck & Co. Inc. / Moderna Inc. (mRNA-4157/V940 option exercise) — 2022 · $250M
• Merck & Co. Inc. / Orna Therapeutics, Inc. — 2022 · $3.6B
• Merck & Co. Inc. / Taiho Pharmaceutical / Astex Pharmaceuticals — 2020 · $2.5B
• Merck & Co. Inc. / Immune Design Corp. — 2019 · $300M
• Merck & Co. Inc. / Ablynx NV — 2014 · $2.3B
• Merck & Co. Inc. / Endocyte, Inc. — 2012 · $1.0B

← Deal Library  ·  Interactive search  ·  How we score deals